{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"32","upperLimit":"86","value":"66"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"Participants that are estimated to be alive or last known to be alive after Rituximab, High-Dose Methotrexate and Leucovorin treatment.","dispersionType":"95% Confidence Interval","groups":[{"description":"Induction treatment cycles with rituximab, high-dose methotrexate and leucovorin will be administered every 2 weeks for 6 cycles. Two additional consolidation cycles of high-dose methotrexate without rituximab will be administered at 4 weeks and 8 weeks following completion of the combined therapy.\n\nMethotrexate: 6000 mg/m\\^2 will be administered by intravenous infusion over 4 hours after confirming that the recipient patients urine pH is within the range greater than or equal to 7 to less than or equal to 8, and urine output is greater than or equal to 100 mL/hour.\n\nRituximab: 375 mg/m\\^2 intravenous (IV) day 1 of each cycle prior to administration of high-dose methotrexate\n\nLeucovorin: Leucovorin calcium doses will be administered orally or by short intravenous (IV) infusion over 15 minutes","id":"OG000","title":"Rituximab, High-Dose Methotrexate & Leucovorin Treatment"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"Time from treatment start date until date of death or date last known alive, approximately 60 months","title":"Estimated Percentage of Participants Overall Survival","type":"SECONDARY","unitOfMeasure":"percentage of participants"}